- CEO Christophe Weber to retire from Takeda in June 2026
after 12 years
- Julie Kim, president of the U.S. Business Unit, named to
succeed Weber after multi-year succession process
Takeda (TOKYO:4502/NYSE:TAK) announced
today that its Board of Directors made the decision unanimously to
appoint Julie Kim, currently president of Takeda’s U.S. Business
Unit, as the successor to Christophe Weber, Takeda’s president,
chief executive officer (CEO) and representative director, when Mr.
Weber retires from the company in June 2026. Mrs. Kim will be
proposed as a candidate for election to the Board at Takeda’s
Annual General Shareholders Meeting held in June 2026. Mr. Weber
will not hold a Board seat after retiring from Takeda.
“The Board of Directors has unanimously chosen Julie Kim to lead
Takeda into the next chapter, building on the company’s success
under Christophe Weber’s remarkable leadership,” said Masami
Iijima, chair of the Board of Directors meeting and of the
Nomination Committee. “During Christophe’s 12 years of leadership,
Takeda has transformed into a competitive, global R&D-driven
biopharmaceutical company, with a long-term sustainable business
model. We are grateful for his tremendous impact and for his
continued leadership at Takeda and support to Julie over the next
18 months. Julie is an outstanding leader who has made significant
contributions to the company, notably in leading the U.S. business
and the Plasma-Derived Therapies Business Unit previously. She is
an experienced, values-based leader who will fully uphold our
corporate culture and expand the impact we can have for patients
around the world.”
Commenting on the selection process, Mr. Iijima said that “after
undergoing a multi-year succession process, the Board determined
that Julie Kim is the best leader among a strong pool of both
internal and external candidates. The selection process followed by
the Nomination Committee and the Board has been thorough and
exemplary.”
“For several years, I have worked with the Board to ensure a
smooth succession,” said Christophe Weber. “Now is the right time
to appoint my successor given our competitive growth outlook, new
product launches expected from the second half of 2026 onwards and
the anticipated retirement of some external independent directors
in the coming years. The Board’s selection of Julie is outstanding.
I have worked closely with Julie for the past six years and have
witnessed firsthand her values, intellect, grit and dedication to
our people and patients.”
“Takeda is a unique company, and I am deeply honored to have
been chosen to lead it,” said Julie Kim. “Thanks to Christophe’s
phenomenal leadership, Takeda has become a global biopharmaceutical
powerhouse with a promising late-stage pipeline. I am excited to
guide Takeda through the next phase, together with our exceptional
and talented people, while staying true to our strong culture that
is rooted in our values and shaped by a heritage of more than 240
years. I want to thank the Board of Directors for their confidence
in me. I look forward to working with the Board, Takeda’s executive
team and all colleagues to serve and create long-term value for
patients, shareholders and society.”
About Christophe Weber
Christophe Weber joined Takeda in April 2014 as chief operating
officer. He was named president and representative director in June
2014, and subsequently appointed CEO in April 2015. Under Mr.
Weber’s leadership, Takeda has focused on enhancing competitiveness
through globalization and R&D transformation, while fostering a
diverse and inclusive work environment and reinforcing ethical
values and corporate governance.
About Julie Kim Julie Kim
has been the president of the U.S. Business Unit and U.S. country
head since 2022, and a member of the Takeda Executive Team since
2019. With three decades of experience in health care, Mrs. Kim has
held leadership positions at global, regional, country and
functional levels. Her extensive background covers a range of
therapeutic areas, international market access, general management,
marketing and emerging market development.
About Takeda Takeda is focused on creating better health
for people and a brighter future for the world. We aim to discover
and deliver life-transforming treatments in our core therapeutic
and business areas, including gastrointestinal and inflammation,
rare diseases, plasma-derived therapies, oncology, neuroscience and
vaccines. Together with our partners, we aim to improve the patient
experience and advance a new frontier of treatment options through
our dynamic and diverse pipeline. As a leading values-based,
R&D-driven biopharmaceutical company headquartered in Japan, we
are guided by our commitment to patients, our people and the
planet. Our employees in approximately 80 countries and regions are
driven by our purpose and are grounded in the values that have
defined us for more than two centuries. For more information, visit
www.takeda.com.
Important Notice For the purposes of this notice, “press
release” means this document, any oral presentation, any question
and answer session and any written or oral material discussed or
distributed by Takeda Pharmaceutical Company Limited (“Takeda”)
regarding this release. This press release (including any oral
briefing and any question-and-answer in connection with it) is not
intended to, and does not constitute, represent or form part of any
offer, invitation or solicitation of any offer to purchase,
otherwise acquire, subscribe for, exchange, sell or otherwise
dispose of, any securities or the solicitation of any vote or
approval in any jurisdiction. No shares or other securities are
being offered to the public by means of this press release. No
offering of securities shall be made in the United States except
pursuant to registration under the U.S. Securities Act of 1933, as
amended, or an exemption therefrom. This press release is being
given (together with any further information which may be provided
to the recipient) on the condition that it is for use by the
recipient for information purposes only (and not for the evaluation
of any investment, acquisition, disposal or any other transaction).
Any failure to comply with these restrictions may constitute a
violation of applicable securities laws.
The companies in which Takeda directly and indirectly owns
investments are separate entities. In this press release, “Takeda”
is sometimes used for convenience where references are made to
Takeda and its subsidiaries in general. Likewise, the words “we”,
“us” and “our” are also used to refer to subsidiaries in general or
to those who work for them. These expressions are also used where
no useful purpose is served by identifying the particular company
or companies.
Forward-Looking Statements This press release and any
materials distributed in connection with this press release may
contain forward-looking statements, beliefs or opinions regarding
Takeda’s future business, future position and results of
operations, including estimates, forecasts, targets and plans for
Takeda. Without limitation, forward-looking statements often
include words such as “targets”, “plans”, “believes”, “hopes”,
“continues”, “expects”, “aims”, “intends”, “ensures”, “will”,
“may”, “should”, “would”, “could”, “anticipates”, “estimates”,
“projects” or similar expressions or the negative thereof. These
forward-looking statements are based on assumptions about many
important factors, including the following, which could cause
actual results to differ materially from those expressed or implied
by the forward-looking statements: the economic circumstances
surrounding Takeda’s global business, including general economic
conditions in Japan and the United States; competitive pressures
and developments; changes to applicable laws and regulations,
including global health care reforms; challenges inherent in new
product development, including uncertainty of clinical success and
decisions of regulatory authorities and the timing thereof;
uncertainty of commercial success for new and existing products;
manufacturing difficulties or delays; fluctuations in interest and
currency exchange rates; claims or concerns regarding the safety or
efficacy of marketed products or product candidates; the impact of
health crises, like the novel coronavirus pandemic, on Takeda and
its customers and suppliers, including foreign governments in
countries in which Takeda operates, or on other facets of its
business; the timing and impact of post-merger integration efforts
with acquired companies; the ability to divest assets that are not
core to Takeda’s operations and the timing of any such
divestment(s); and other factors identified in Takeda’s most recent
Annual Report on Form 20-F and Takeda’s other reports filed with
the U.S. Securities and Exchange Commission, available on Takeda’s
website at:
https://www.takeda.com/investors/sec-filings-and-security-reports/
or at www.sec.gov. Takeda does not undertake to update any of the
forward-looking statements contained in this press release or any
other forward-looking statements it may make, except as required by
law or stock exchange rule. Past performance is not an indicator of
future results and the results or statements of Takeda in this
press release may not be indicative of, and are not an estimate,
forecast, guarantee or projection of Takeda’s future results.
Medical Information This press release contains
information about products that may not be available in all
countries, or may be available under different trademarks, for
different indications, in different dosages, or in different
strengths. Nothing contained herein should be considered a
solicitation, promotion or advertisement for any prescription drugs
including the ones under development.
(Attachment)
1. Changes in Appointment and Titles of
Representative Directors
Name
New Title (planned)
Current Title
Julie Kim
Representative Director, President &
Chief Executive Officer*
President, U.S. Business Unit and U.S.
Country Head
Christophe Weber
Retirement
Representative Director, President &
Chief Executive Officer
* Subject to election and appointment at
the 150th Ordinary General Meeting of Shareholders and Board of
Directors meeting in June 2026.
2. Biography of Newly Appointed
Representative Director
Date of Birth
Business Experience
Number of ADSs Held*
June 6, 1970
June 2016
Joined Shire plc
95,065 ADSs
June 2016
Head of International Value Demonstration
& Access
May 2018
Head of Global Hematology Franchise
January 2019
Joined Takeda Pharmaceutical Company
Limited
January 2019
President, Plasma-Derived Therapies
Business Unit
April 2022
President, U.S. Business Unit, and U.S.
Country Head
(to present)
*There are no ordinary shares held as of
the filing date.
3. Effective Date of Changes (planned) June 2026
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250129509380/en/
Takeda Media Relations Amy Atwood (U.S. & Global)
amy.atwood@takeda.com
Aya Shishido (Japan) aya.shishido@takeda.com
Takeda Investor Relations Christopher O’Reilly
Christopher.oreilly@takeda.com +81 (0) 90-6481-3412
Takeda Pharmaceutical (NYSE:TAK)
과거 데이터 주식 차트
부터 2월(2) 2025 으로 3월(3) 2025
Takeda Pharmaceutical (NYSE:TAK)
과거 데이터 주식 차트
부터 3월(3) 2024 으로 3월(3) 2025
